Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ginisortamab, an antibody targeting GREM1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bafisontamab, an antibody targeting EGFR × MET.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dresbuxelimab, an antibody targeting CD73.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Betifisolimab, an antibody targeting PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vonsetamig, an antibody targeting BCMA × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Acrixolimab, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zovostotug, an antibody targeting CD163.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nezutatug, an antibody targeting HER3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Polzastobart, an antibody targeting LILRB2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Puxitatug, an antibody targeting VTCN1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Davutamig, an antibody targeting MET.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Firastotug, an antibody targeting CTLA-4.